Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 10,750,000 shares, an increase of 5.8% from the December 15th total of 10,160,000 shares. Approximately 19.8% of the company’s shares are sold short. Based on an average daily volume of 824,600 shares, the short-interest ratio is presently 13.0 days.

Structure Therapeutics Stock Up 0.3 %

Structure Therapeutics stock traded up $0.08 during trading hours on Monday, hitting $27.06. The stock had a trading volume of 846,835 shares, compared to its average volume of 770,004. The stock has a market capitalization of $1.55 billion, a P/E ratio of -36.57 and a beta of -2.78. The stock’s 50-day moving average price is $30.78 and its 200-day moving average price is $36.03. Structure Therapeutics has a 12-month low of $23.50 and a 12-month high of $62.74.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on GPCR shares. JMP Securities reiterated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of “Buy” and an average price target of $81.29.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the last quarter. Sandia Investment Management LP purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $39,000. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $40,000. Assetmark Inc. lifted its position in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the period. Finally, Quarry LP purchased a new stake in Structure Therapeutics in the second quarter worth approximately $79,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.